JamesBBusselMD

Pediatric Hematology & Oncology • New York, NY

Professor of Pediatrics, Cornell University-Weill Medical College

Join to view full profile

Dr. Bussel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bussel's full profile

Already have an account?

Office
525 E 68th St
# P-695
New York, NY 10065
Phone+1 212-746-3400

Fax+1 212-746-3988

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1980 - 1981
Cincinnati Children's Hospital Medical CenterResidency, Pediatrics, 1975 - 1978
Columbia University Vagelos College of Physicians and SurgeonsClass of 1975

Certifications & Licensure

NY State Medical License 1978 - 2026
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2002-2014
Top Doctors: New York Metro Area Castle Connolly, 2002-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
New York Magazine: Top Doctors Castle Connolly, 2002-2013
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Super Doctor SuperDoctors.com
Whos Who in Medicine and Healthcare Marquis Whos Who
Join now to see all

Clinical Trials

Optimal Platelet Dose Strategy for Management of Thrombocytopenia Start of enrollment: 2004 Jul 01
Completed
Phase 3
A Trial to Treat Patients With ITP Who Do Not Achieve a Durable Response to Rituxan Alone Start of enrollment: 2004 Feb 01
Withdrawn
Phase 2
A Trial of Antenatal Treatment of Alloimmune Thrombocytopenia Start of enrollment: 2001 Apr 01
Completed
Phase 2, Phase 3
Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP Start of enrollment: 2003 Jul 01
Completed
Phase 2
Fresh-Frozen Plasma Infusions to Reduce Risk of Bleeding Related to Invasive Procedures Start of enrollment: 2006 Mar 01
Withdrawn
Phase 3
Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection Start of enrollment: 2005 Mar 01
Terminated
Phase 4
Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpura Start of enrollment: 2005 Nov 01
Withdrawn
Phase 1, Phase 2
Safety and Effectiveness of Granulocyte Transfusions in Resolving Infection in People With Neutropenia (The RING Study) Start of enrollment: 2008 Apr 01
Completed
Phase 3
Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP Start of enrollment: 2003 Nov 01
Completed
Phase 2, Phase 3
Evaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopenic Purpura (TTP) Start of enrollment: 2009 Apr 01
Terminated
Phase 3
Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP) Start of enrollment: 2009 Jan 01
Completed
Phase 2
Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients Start of enrollment: 2009 Jun 01
Terminated
Phase 2
Red Cell Storage Duration Study Start of enrollment: 2010 Jan 01
Completed
Phase 3
Initial Treatment of Patients With Immune Thrombocytopenic Purpura Start of enrollment: 2010 Jan 01
Terminated
Phase 3
Heparin-Induced Thrombocytopenia - Retrospective Analysis of Data on Incidence and Outcomes Study Start of enrollment: 2010 Jun 01
Completed
End of EXTEND: Discontinuation of Medication for Patients With Immune Thrombocytopenia Start of enrollment: 2011 Jun 01
Terminated
Genome-Wide Gene Expression Profiling of Patients With ITP Receiving Thrombopoietin Mimetics Start of enrollment: 2012 Jul 01
Completed
Safety and Efficacy of Eltrombopag at Escalated Doses Start of enrollment: 2013 Feb 01
Completed
Phase 2
ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP Start of enrollment: 2013 Aug 01
Completed
A Chart Review of Rituximab Plus Repeated Cycles of Dexamethasone Start of enrollment: 2011 Jan 01
Terminated
A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) Start of enrollment: 2014 Jul 14
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

Primary versus Secondary Immune Thrombocytopenia (ITP): A Meeting Report from the 2023 McMaster ITP Summit.
Dimpy Modi, Saifur R Chowdhury, Syed Mahamad, Hayley Modi, Douglas B Cines
Thrombosis and Haemostasis. 2025-01-20
1 citations
MicroRNA-199a-5p may be a diagnostic biomarker of primary ITP.
Lamya Garabet, Anbjørg Rangberg, Anna Maria Eriksson, Christine Monceyron Jonassen, Raul Teruel-Montoya
British Journal of Haematology. 2025-01-07
Inhibition of FcRn with rozanolixizumab in adults with immune thrombocytopenia: Two randomised, double-blind, placebo-controlled phase 3 studies and their open-label e...
Nichola Cooper, James B Bussel, Maciej Kaźmierczak, Yoshitaka Miyakawa, Sarah Cluck
British Journal of Haematology. 2024-11-18

Abstracts/Posters

The Burden of Disease and IMPACT of Immune Thrombocytopenia (ITP) on Patients: Results from an ITP Survey
James B. Bussel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Hyper-Sialylated IgG M254, an Innovative Therapeutic Candidate, Evaluated in Healthy Volunteers and in Patients with Immune Thrombocytopenia Purpura: Safety, Tolerabil...
James B. Bussel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
PhysiciansÍ and PatientsÍ Perspectives on Treatments in ITP _ a Multi-Country Perspective: Results from the ITP World Impact Survey (I-WISh)
James B. Bussel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Rozanolixizumab, an Anti-FcRn Antibody: Final Results from a Phase II, Multiple-Dose Study in Patients with Primary Immune ThrombocytopeniaClinically Relevant Abstract
James B. Bussel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Enhanced Responses to Fostamatinib As Second-Line Therapy and in Persistent Immune Thrombocytopenia (ITP) Patients
James B. Bussel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Updated Results from the Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)Cli...
James B. Bussel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Dose-Dependent Iron Chelating Effects of Eltrombopag on in Vitro Human Megakaryopoiesis
James B. Bussel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Potentiating the Power of Platelets: Examining the Clinical Utility of Multiple Thrombopoietin Receptor Agonists in ITP, Chemotherapy Induced Thrombocytopenia and Live...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Patients with Immune Thrombocytopenia (ITP) Frequently Experience Severe Fatigue but Is It Under-Recognized By Physicians: Results from the ITP World Impact Survey (I-...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Platelets 2012 International Symposium
Jonathan Wood & Associates, Beverly, Massachusetts - 6/7/2012

Other

Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in children
Bussel JB
http://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-immune-thrombocytopenia-it
UpToDate, Wolters Kluwer Health - 2013-03-29

Press Mentions

Dramatic Increase in Response with Combination for Relapsed/Resistant ITPJanuary 28th, 2022
Adding Mycophenolate Mofetil Improves Outcomes in ITPSeptember 1st, 2021
The Faces I’ll Remember, Long After I Put My Notebook DownJune 18th, 2021
Join now to see all

Grant Support

Novel Therapies In Hemostasis And TransfusionNational Heart, Lung, And Blood Institute2007–2009
Novel Therapies In Hemostasis And Transfusion MedicineNational Heart, Lung, And Blood Institute2002–2006
Rituxan Comparison Standard VS Combination With CVP In ITPNational Center For Research Resources2005
OPEN Label, Phase I/II Trial Of Rituximab For Chronic, Severe, Idiopathic ThromNational Center For Research Resources2005